MONTREAL, March 27 /CNW Telbec/ - Akela Pharma Inc. (TSX: “AKL”), a drug development company focused on developing therapies for the inhalation and pain markets, today announced that it has closed its previously announced offering for gross proceeds of Cdn $10.35 million. A total of 8,625,000 units were issued at a price of Cdn $1.20 per unit, of which 3,750,000 units were underwritten, 3,750,000 units were on a best efforts basis and 1,125,000 units were issued under the overallotment option. The offering was led by Jennings Capital Inc. and included Desjardins Securities Inc. (together the “Underwriters”).
